Amerikanische Gesellschaft für Hirudotherapie

Fiji Ministry of Health and Medical Services — Pharmacy and Therapeutics Section

Fiji PTS · Fiji · oceania

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Fiji's Pharmacy and Therapeutics Section (under the Ministry of Health and Medical Services) — leech-specific regulatory pathway has not been independently verified by ASH; medicinal leeches fall under the general national medical device framework as appropriate.

Regulatory Profile

Agency type
national regulator
Region
oceania
Country
Fiji
Leech status
unregulated
Last ASH review
2026-05-26

Relevant Regulation Codes

  • Fijian Medicinal Products Act and subsidiary regulations
  • Fijian national medical device regulatory framework

Prescriber Requirements

  • Fiji Medical Council–registered physician — order required for any biomedical device application
  • Allied health professional application under physician supervision per institutional protocol

Supply Chain & GMP

Ministry of Health registration as applicable; English-language labelling. Standard cold-chain conditions, with logistical constraints typical for Pacific island states.

Import/Export Rules

Ministry of Health import authorisation; Biosecurity Authority of Fiji clearance for live invertebrates; CITES Appendix II paperwork for Hirudo medicinalis / verbana.

Reimbursement Context

Not covered under public insurance schemes for leech therapy specifically.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; falls under general medical device / traditional medicine framework as appropriate. Pacific island regulatory frameworks often rely on regional harmonisation with Australia (TGA) and New Zealand (Medsafe); the exact mechanism has not been independently mapped by ASH.

Related Jurisdictions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.